IndraLab

Statements


| 1

sparser
"In the current study, we have also observed that all patients with ERBB2 alterations (N=8) harbored at least one co-alteration, including anomalies in FGFR2 , RAF1 , PIK3CA and KRAS that can be associated with resistance to anti-HER2 regimens ( xref , patient ID: 1, 4, 17, 30, 32, 33, 47 and 53)."